XML 34 R6.htm IDEA: XBRL DOCUMENT v3.19.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Dec. 31, 2018
Cash flows from operating activities:          
Net loss $ (5,476,807) $ (4,656,386) $ (13,748,774) $ (17,363,937)  
Adjustments to reconcile net loss to net cash from operating activities;          
Depreciation and amortization     537,211 261,513  
Change in fair value of earn-out milestone liability     (3,088,821) (3,567,671)  
Fair value of warrants issued in connection with amendment to modify the GEN-1 earn-out milestone payments 400,000  
Impairment of in-process research and development 4,510,000 4,510,000  
Recognition of deferred revenue     (375,000) (375,000)  
Stock-based compensation costs     1,762,172 3,985,829  
Shares issued in exchange for services     5,350 29,841  
Amortization of deferred finance charges and debt discount associated with notes payable     289,182 101,695  
Change in deferred rent liability     (6,009)  
Net changes in:          
Accrued interest on investment securities     41,338 (22,306)  
Advances, deposits and other current assets     (951,877) (281,991)  
Accounts payable and accrued liabilities     486,857 (399,935)  
Net cash (used in) operating activities:     (14,642,362) (13,127,971)  
Cash flows from investing activities:          
Purchases of investment securities     (19,338,177) (15,574,587)  
Proceeds from sale and maturity of investment securities     23,310,000 9,750,000  
Purchases of property and equipment     (336,445) (81,778)  
Net cash provided by (used for) investing activities     3,635,378 (5,906,365)  
Cash flows from financing activities:          
Proceeds from sale of common stock equity, net of issuance costs     6,175,527 1,236,584  
Proceeds received from notes payable, net of issuance costs     9,725,000  
Net cash provided by financing activities     6,157,527 10,961,584  
Decrease in cash and cash equivalents     (4,831,457) (8,072,752)  
Cash and cash equivalents at beginning of period     13,353,543 11,444,055 $ 11,444,055
Cash and cash equivalents at end of period 8,522,086 3,371,303 8,522,086 3,371,303 $ 13,353,543
Supplemental disclosures of cash flow information:          
Interest paid     760,615 259,064  
Cash paid for amounts included in measurement of lease liabilities:          
Operating cash flows from lease payments 130,631 111,977 355,216  
Non-cash financing and investing activities          
Fair value of warrants issued in connection with amendment to modify the GEN-1 earn-out milestone payments     400,000  
Fair value of common stock issued as equity issuance costs and charged against paid in capital     450,000  
Fair value of warrants issued in connection with the debt facility     507,116  
Right of use assets obtained in exchange for lease liabilities          
Operating leases     1,797,561  
Realized and unrealized gains and losses, net, on investment securities $ (60,501) $ 25,207 $ 4,203 $ 31,124